Suven Pharmaceuticals Share Price

NSE: COHANCE
|
Pharmaceuticals

₹ 445.60

+₹8.25 (1.89%)
1D
Last updated 14 Oct, 2026, 15:56 IST

Suven Pharmaceuticals Share Price Today

As of 14 Oct 2026, Suven Pharmaceuticals share price is ₹445.60. The stock opened at ₹436.10, compared to its previous close of ₹437.35. During today's trading session, Suven Pharmaceuticals share price moved in the range of ₹432.25 to ₹448.80, with an average price of ₹440.52 for the day. Looking at its last 52-week, the stock has touched a low of ₹266.70 and a high of ₹917.85. On the performance front, Suven Pharmaceuticals share price has increased by 24.26% over the last six months and is down 48.60% on a year-on-year basis.

₹432.25
1.89% up today
₹448.80
1D LOW
1D HIGH

Suven Pharmaceuticals Returns Calculator

Volume
4,66,904
Average traded price
₹441.52
Last traded time
03:56:47 14 Oct
Last traded quantity
59
Circuit
L
H
₹349.90
₹524.80
52-week
L
H
₹266.70
₹917.85
Mkt Cap Cr
16,727.16
P/E
285.75
P/B
4.28
ROA
1.02%
ROE
5.05%
ROCE
5.47%
Quick Ratio
1.91
EV/EBITDA
53.05
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Cohance Life outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Cohance Life appears overvalued compared to its peers
Step 1 of 5
Earnings
Very Poor
Cohance Life revenue, operating profits and net profits have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0135.035.0811.19%13.74%17.33%2.3121.42
Divis Laboratories2,46,222.1184.1814.6914.6%15.32%19.56%3.556.81
Torrent Pharmaceuticals1,76,300.5081.7720.964.87%25.49%13.85%0.7538.3
Zydus Lifesciences1,12,817.6824.574.168.57%18.59%17.35%0.9115.07
Laurus Labs1,11,898.66101.6420.9110.38%16.77%16.14%0.6854.71
Cipla1,06,129.9632.023.127.92%11.27%14.95%2.517.97
Dr. Reddy's Laboratories1,03,471.1432.52.725.48%11.07%12.54%1.3516.27
Mankind Pharma99,089.5247.326.07.36%11.74%13.13%0.7426.02
Aurobindo Pharma96,836.1026.12.566.34%9.25%11.76%1.1512.57
Lupin89,628.8316.153.9914.47%23.76%24.88%1.429.46

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Suven Pharmaceuticals

ISIN
INE03QK01018
Sector Market Cap
₹ 16,727.16 Cr

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.

Suven Pharmaceuticals Financial Highlights

  • Revenue: Suven Pharmaceuticals reported revenue of ₹2,302.64 crore in FY26 vs ₹2,677.71 crore in FY25. It showed a decrease of 14.01% on a yearly basis.
  • Operating Profit: Suven Pharmaceuticals reported an operating profit of ₹207.04 crore in FY26 vs ₹642.63 crore in FY25. It showed a decrease of 67.78% on a year-on-year basis.
  • Net Profit: Suven Pharmaceuticals reported a net profit of ₹150.12 crore in FY26 vs ₹484.24 crore in FY25. It showed a decrease of 69.00% on a yearly basis.

Suven Pharmaceuticals Quarterly Result Highlights

  • Suven Pharmaceuticals reported revenue of ₹434.51 crore in Jun 2026, compared with ₹617.28 crore in Mar 2026, representing a decrease of 29.61% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported an operating loss of ₹42.87 crore in Jun 2026, compared with ₹19.91 crore in Mar 2026, representing a decrease of 315.32% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported a loss of ₹45.19 crore in Jun 2026, compared with ₹8.31 crore in Mar 2026, reflecting a decrease of 643.80% on a QoQ basis.
  • The earnings per share (EPS) of Suven Pharmaceuticals stood at ₹4.69 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
57.49%
FII
6.50%
Other DII
1.88%
Retail and other
15.93%
Mutual funds
18.21%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20256.51%
Dec 20256.02%
Mar 20265.59%
Jun 20266.50%
1 day
+1.89%
1 week
-2.16%
1 month
+1.23%
1 year
-48.60%
3 years
-24.47%
5 years
-17.40%
Day
Open / Close
Change %
13 Oct 26
₹447.50 / ₹437.35
-1.60%
12 Oct 26
₹446.60 / ₹444.45
+0.78%
09 Oct 26
₹444.90 / ₹441.00
-0.32%
08 Oct 26
₹456.00 / ₹442.40
-2.87%
Show more

Suven Pharmaceuticals Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,268.55₹2,608.50₹1,051.35₹1,340.33
Other Income₹34.09₹69.21₹61.91₹46.36
Total Revenue₹2,302.64₹2,677.71₹1,113.26₹1,386.69
Total Expenses₹2,066.13₹2,019.30₹707.59₹826.96
Profit Before Tax₹207.04₹642.63₹405.67₹559.73
Tax₹56.92₹158.39₹105.39₹148.44
Profit After Tax₹150.12₹484.24₹300.28₹411.29
EPS - Basic₹4.69₹12.79₹11.80₹16.16
EPS - Diluted₹4.68₹12.68₹11.80₹16.16

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹207.04₹642.63₹405.67₹559.73
Income before WC changes₹415.33₹849.99₹421.02₹597.19
Change in Assets₹7.92₹7.15₹70.44₹59.22
Change in Liabilities₹12.84-₹7.88-₹23.03-₹53.45
Change in WC₹20.76-₹0.73₹47.41₹5.77
Cash flow from Operations₹368.32₹673.35₹358.48₹457.20
Cash flow from Investing-₹254.57-₹389.70-₹362.25-₹195.01
Cash flow from Financing-₹165.15-₹327.40-₹13.80-₹241.95
Total Cash Flow-₹51.40-₹43.75-₹17.57₹20.24
Cash (Start of the year)₹96.65₹138.32₹64.80₹44.56
Cash (End of the year)₹49.14₹96.65₹47.23₹64.80

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,933.38₹3,722.79₹990.90₹954.70
Current Assets₹1,796.26₹1,758.17₹1,263.19₹1,011.05
Total Assets₹5,729.64₹5,480.96₹2,254.09₹1,965.74
Current Liabilities₹645.93₹705.41₹106.90₹158.77
Net Current Asset₹1,150.33₹1,052.76₹1,156.29₹852.28
Non-Current Liabilities₹1,049.88₹982.67₹96.53₹71.79
Equity Capital₹4,033.83₹3,792.88₹2,050.66₹1,735.18
Total Equity & Liabilities₹5,729.64₹5,480.96₹2,254.09₹1,965.74

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,030.50₹2,504.43₹1,051.35₹1,330.08
Other Income₹44.73₹64.84₹56.61₹44.55
Total Revenue₹2,075.23₹2,569.27₹1,107.96₹1,374.63
Total Expenses₹1,732.13₹1,903.43₹707.54₹795.24
Profit Before Tax₹313.63₹650.06₹400.42₹579.39
Tax₹84.92₹158.88₹103.95₹146.79
Profit After Tax₹228.71₹491.18₹296.47₹432.60
EPS - Basic₹5.98₹12.89₹11.65₹16.99
EPS - Diluted₹5.97₹12.80₹11.65₹16.99

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹313.63₹650.06₹400.42₹579.39
Income before WC changes₹426.55₹838.83₹417.56₹615.08
Change in Assets₹27.45₹11.17₹90.72₹79.68
Change in Liabilities₹2.65₹9.08-₹23.56-₹56.15
Change in WC₹30.10₹20.25₹67.16₹23.53
Cash flow from Operations₹389.57₹686.23₹376.20₹492.82
Cash flow from Investing-₹204.29-₹455.35-₹362.40-₹236.86
Cash flow from Financing-₹202.78-₹309.91-₹39.99-₹243.14
Total Cash Flow-₹17.50-₹79.03-₹26.19₹12.81
Cash (Start of the year)₹30.61₹109.55₹44.65₹30.21
Cash (End of the year)₹13.11₹30.61₹18.46₹43.02

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,444.53₹3,423.54₹990.65₹1,003.21
Current Assets₹1,668.67₹1,613.51₹1,224.23₹955.12
Total Assets₹5,113.20₹5,037.05₹2,214.88₹1,958.33
Current Liabilities₹504.71₹553.78₹117.15₹154.18
Net Current Asset₹1,163.96₹1,059.73₹1,107.08₹800.94
Non-Current Liabilities₹128.38₹215.50₹69.38₹54.77
Equity Capital₹4,480.11₹4,267.77₹2,028.35₹1,749.38
Total Equity & Liabilities₹5,113.20₹5,037.05₹2,214.88₹1,958.33
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
445.6
3357
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 3357
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
4
Bullish
3
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
44.18
Neutral
ATR (14)
15.62
Neutral
STOCH(9,6)
20.52
Bullish
STOCH RSI (14)
0
Bullish
ADX(9)
17.61
Bullish
UO(9)
42.28
Neutral
ROC(12)
-3.7
Bearish
WillR(14)
-79.48
Neutral
Period
Simple value
Exponential vaue
5D
444.13
443.13
10D
447.77
446.09
20D
447.68
447.81
50D
448.51
446.3
100D
441.57
435.58
Volume trend — traded volume by day
14 Oct4L
13 Oct4L
12 Oct2L
9 Oct4L
8 Oct8L
7 Oct13L
Average6L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Suven Pharmaceuticals
Pharmaceuticals
Add Stock
Add Another

Suven Pharmaceuticals Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.